Index -
P/E -
EPS (ttm) -0.07
Insider Own 40.77%
Shs Outstand 74.98M
Perf Week 8.75%
Market Cap 262.08M
Forward P/E 60.52
EPS next Y 0.06
Insider Trans 0.02%
Shs Float 44.60M
Perf Month 102.33%
Income -4.94M
PEG -
EPS next Q -0.02
Inst Own 15.50%
Short Float 2.63%
Perf Quarter 140.00%
Sales 83.57M
P/S 3.14
EPS this Y 78.57%
Inst Trans -19.26%
Short Ratio 5.48
Perf Half Y 140.00%
Book/sh 0.38
P/B 9.17
EPS next Y 483.33%
ROA -9.06%
Short Interest 1.17M
Perf Year 124.52%
Cash/sh 0.36
P/C 9.59
EPS next 5Y -
ROE -17.29%
52W Range 1.25 - 4.06
Perf YTD 143.36%
Dividend Est. -
P/FCF 38.04
EPS past 5Y 35.83%
ROI -15.91%
52W High -14.28%
Beta 1.99
Dividend TTM -
Quick Ratio 1.70
Sales past 5Y 22.27%
Gross Margin 60.76%
52W Low 178.40%
ATR (14) 0.35
Dividend Ex-Date -
Current Ratio 2.40
EPS Y/Y TTM 72.60%
Oper. Margin -3.95%
RSI (14) 71.71
Volatility 16.03% 13.97%
Employees 106
Debt/Eq 0.12
Sales Y/Y TTM 15.99%
Profit Margin -5.91%
Recom 1.00
Target Price 5.91
Option/Short Yes / Yes
LT Debt/Eq 0.09
EPS Q/Q 107.81%
Payout -
Rel Volume 2.27
Prev Close 3.67
Sales Surprise 1.84%
EPS Surprise 100.00%
Sales Q/Q 0.95%
Earnings Mar 06 AMC
Avg Volume 214.23K
Price 3.48
SMA20 42.62%
SMA50 83.64%
SMA200 118.46%
Trades
Volume 486,389
Change -5.18%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-16-22 Downgrade
Oppenheimer
Outperform → Perform
Aug-11-22 Downgrade
B. Riley Securities
Buy → Neutral
$6 → $2.40
Mar-08-22 Initiated
ROTH Capital
Buy
$7
Oct-16-19 Initiated
Oppenheimer
Outperform
$6
Feb-14-19 Initiated
B. Riley FBR
Buy
$7
Nov-27-17 Resumed
H.C. Wainwright
Buy
$6 → $8
Sep-25-17 Initiated
Ladenburg Thalmann
Buy
$7
Jan-03-17 Initiated
Rodman & Renshaw
Buy
$6
Mar-26-24 08:32AM
Mar-07-24 01:59PM
10:37AM
06:27AM
(Thomson Reuters StreetEvents)
Mar-06-24 09:53PM
04:04PM
Loading…
04:04PM
Feb-21-24 08:32AM
Feb-05-24 08:32AM
Jan-26-24 04:08PM
Dec-20-23 09:04AM
Dec-12-23 10:30AM
Nov-30-23 08:34AM
Nov-15-23 08:32AM
Nov-10-23 12:54PM
Nov-09-23 08:32AM
06:33PM
Loading…
Nov-08-23 06:33PM
04:48PM
(Associated Press Finance)
04:02PM
Nov-01-23 08:34AM
Oct-31-23 08:34AM
Oct-26-23 08:32AM
Oct-02-23 08:32AM
Aug-24-23 08:32AM
Aug-12-23 09:04AM
Aug-10-23 10:38AM
(Thomson Reuters StreetEvents)
Aug-09-23 05:40PM
04:37PM
(Associated Press Finance)
04:02PM
Aug-08-23 08:34AM
Aug-07-23 08:32AM
08:02AM
Loading…
Aug-02-23 08:02AM
Jul-18-23 08:32AM
Jun-16-23 08:32AM
Jun-08-23 08:19AM
May-30-23 08:34AM
May-11-23 08:34AM
May-10-23 05:35PM
04:32PM
04:02PM
May-02-23 08:32AM
06:31AM
Apr-12-23 01:04PM
Mar-27-23 06:43AM
Mar-10-23 05:23AM
02:28AM
Mar-09-23 09:06AM
(Thomson Reuters StreetEvents) -10.38%
Mar-08-23 06:25PM
04:02PM
Mar-06-23 08:34AM
Mar-02-23 10:00AM
Mar-01-23 10:00AM
Feb-27-23 08:32AM
Feb-22-23 08:34AM
Feb-21-23 08:32AM
Jan-31-23 08:32AM
Jan-17-23 08:28AM
Jan-15-23 08:52AM
Jan-12-23 08:34AM
Jan-05-23 08:33AM
Dec-27-22 08:30AM
Dec-19-22 09:35AM
Dec-16-22 09:35AM
Nov-11-22 08:12AM
Nov-09-22 05:02AM
Nov-02-22 05:35PM
04:02PM
11:40AM
Oct-26-22 08:35AM
Oct-24-22 08:32AM
Oct-11-22 07:32AM
Oct-06-22 08:53AM
Oct-04-22 06:32AM
Oct-03-22 07:30AM
Sep-19-22 06:05PM
Sep-01-22 06:32AM
Aug-29-22 03:07PM
Aug-24-22 09:00AM
(American City Business Journals)
09:00AM
Aug-15-22 06:34AM
Aug-10-22 05:45PM
04:02PM
Aug-08-22 09:41AM
Aug-02-22 06:32AM
Jul-10-22 09:57AM
Jul-07-22 06:32AM
Jun-22-22 06:07AM
Jun-15-22 06:34AM
Jun-10-22 06:32AM
Jun-07-22 01:33PM
Jun-02-22 06:34AM
Jun-01-22 06:32AM
May-22-22 08:17AM
May-20-22 10:02AM
May-19-22 04:34PM
May-17-22 08:27AM
(Simply Wall St.) +15.09%
06:34AM
May-12-22 05:35PM
04:03PM
May-09-22 08:25AM
May-05-22 08:35PM
Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm's proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Gerber Brianna Chief Financial Officer Dec 01 '23 Buy 1.41 5,000 7,050 27,436 Dec 04 04:12 PM Jaksch Frank L Jr Director Jun 12 '23 Buy 1.69 7,000 11,830 231,339 Jun 13 04:50 PM Fried Robert N Chief Executive Officer May 31 '23 Buy 1.42 7,000 9,940 95,001 Jun 01 04:27 PM Rubin Steven D Director May 25 '23 Buy 1.46 7,000 10,220 7,000 May 30 04:13 PM
Index -
P/E 11.50
EPS (ttm) 8.71
Insider Own 6.27%
Shs Outstand 56.50M
Perf Week 5.70%
Market Cap 5.65B
Forward P/E 10.87
EPS next Y 9.21
Insider Trans 0.00%
Shs Float 52.86M
Perf Month 7.82%
Income 502.80M
PEG 0.77
EPS next Q 0.04
Inst Own 85.82%
Short Float 6.54%
Perf Quarter 3.98%
Sales 8.93B
P/S 0.63
EPS this Y -13.45%
Inst Trans -6.28%
Short Ratio 4.98
Perf Half Y -1.56%
Book/sh 25.10
P/B 3.99
EPS next Y 16.18%
ROA 9.37%
Short Interest 3.46M
Perf Year -6.47%
Cash/sh 6.52
P/C 15.35
EPS next 5Y 15.00%
ROE 39.95%
52W Range 82.00 - 138.49
Perf YTD 5.65%
Dividend Est. 2.65 (2.65%)
P/FCF 10.26
EPS past 5Y 10.70%
ROI 14.84%
52W High -27.71%
Beta 1.60
Dividend TTM 2.61 (2.61%)
Quick Ratio 0.46
Sales past 5Y 8.11%
Gross Margin 21.33%
52W Low 22.10%
ATR (14) 2.38
Dividend Ex-Date Feb 29, 2024
Current Ratio 1.39
EPS Y/Y TTM -11.88%
Oper. Margin 7.02%
RSI (14) 69.83
Volatility 2.50% 2.40%
Employees 18500
Debt/Eq 1.45
Sales Y/Y TTM 1.94%
Profit Margin 5.63%
Recom 2.56
Target Price 98.15
Option/Short Yes / Yes
LT Debt/Eq 1.39
EPS Q/Q -45.85%
Payout 29.84%
Rel Volume 0.85
Prev Close 99.08
Sales Surprise 2.01%
EPS Surprise -22.62%
Sales Q/Q -4.78%
Earnings Jan 30 BMO
Avg Volume 693.56K
Price 100.12
SMA20 7.76%
SMA50 8.72%
SMA200 -1.96%
Trades
Volume 592,953
Change 1.05%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-17-24 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$103 → $113
Sep-27-23 Resumed
Morgan Stanley
Equal-Weight
$120
Jul-18-23 Downgrade
Raymond James
Strong Buy → Mkt Perform
Apr-19-23 Initiated
KeyBanc Capital Markets
Overweight
$125
Jan-27-23 Downgrade
UBS
Buy → Neutral
$165 → $112
Jan-13-23 Downgrade
Northcoast
Buy → Neutral
Dec-08-22 Downgrade
BMO Capital Markets
Outperform → Market Perform
$120 → $110
Nov-30-22 Initiated
MKM Partners
Neutral
$117
Oct-19-22 Downgrade
Citigroup
Buy → Neutral
$131 → $101
Jun-28-22 Initiated
Jefferies
Hold
$105
May-05-22 Initiated
DA Davidson
Neutral
$99
Feb-10-22 Initiated
Citigroup
Buy
$157
Jul-01-21 Downgrade
Longbow
Buy → Neutral
Jun-14-21 Initiated
Exane BNP Paribas
Underperform
$113
Apr-26-21 Downgrade
Citigroup
Buy → Neutral
$160
Mar-19-21 Reiterated
Morgan Stanley
Overweight
$145 → $158
Jan-20-21 Upgrade
BMO Capital Markets
Market Perform → Outperform
$100 → $136
Jan-20-21 Initiated
Morgan Stanley
Overweight
$140
Jan-19-21 Reiterated
Wedbush
Outperform
$116 → $126
Oct-05-20 Upgrade
Robert W. Baird
Neutral → Outperform
$122
Show Previous Ratings
Mar-25-24 05:44PM
07:00AM
Mar-20-24 12:00PM
Mar-07-24 05:40PM
09:05AM
07:00AM
Loading…
Mar-05-24 07:00AM
Mar-04-24 11:58AM
Mar-01-24 08:52AM
Feb-28-24 04:32PM
Feb-20-24 12:00PM
Feb-16-24 03:51AM
Feb-13-24 10:01AM
Feb-09-24 11:36AM
Feb-06-24 12:00PM
Feb-04-24 06:54PM
04:15PM
Loading…
Feb-01-24 04:15PM
10:33AM
Jan-30-24 02:13PM
02:01PM
10:45AM
09:30AM
07:10AM
06:00AM
Jan-29-24 05:45PM
Jan-23-24 10:00AM
Jan-19-24 02:55PM
Jan-12-24 11:45PM
Jan-11-24 07:00AM
Jan-04-24 03:27PM
Dec-27-23 12:00PM
07:00AM
Loading…
07:00AM
Dec-14-23 03:07PM
Dec-08-23 10:23AM
Dec-05-23 11:01AM
Dec-01-23 08:03AM
Nov-25-23 07:30AM
Nov-20-23 08:27PM
Nov-16-23 10:37AM
Nov-15-23 09:30AM
Nov-09-23 04:15PM
Nov-07-23 12:01PM
Oct-31-23 06:30AM
Oct-26-23 04:15PM
08:07AM
Oct-25-23 12:59PM
Oct-24-23 09:37AM
09:35AM
06:00AM
Oct-23-23 12:02PM
Oct-17-23 10:00AM
Oct-05-23 07:00PM
Sep-27-23 06:00AM
Sep-19-23 10:00AM
Sep-13-23 09:40AM
Sep-11-23 05:07PM
Sep-05-23 04:48PM
Aug-28-23 02:00PM
11:30AM
11:00AM
Aug-23-23 02:02PM
Aug-22-23 05:45PM
Aug-21-23 09:40AM
Aug-15-23 01:46PM
Aug-10-23 11:00AM
Aug-09-23 01:54PM
Jul-31-23 07:15AM
07:02AM
Jul-27-23 04:15PM
Jul-26-23 12:14PM
11:00AM
Jul-25-23 12:18PM
06:00AM
Jul-12-23 09:02AM
Jul-11-23 11:00AM
Jul-04-23 07:00AM
Jun-27-23 01:31PM
07:00AM
Jun-22-23 12:25PM
Jun-21-23 08:00PM
Jun-09-23 07:59AM
Jun-07-23 01:00PM
Jun-05-23 01:38PM
Jun-01-23 07:00AM
May-30-23 12:00PM
May-26-23 06:37AM
May-22-23 06:11AM
May-18-23 10:00AM
May-17-23 11:05AM
May-16-23 12:00PM
May-15-23 06:40AM
May-01-23 06:12AM
Apr-28-23 12:55PM
Apr-27-23 04:15PM
Apr-26-23 08:00PM
Apr-25-23 06:00AM
Apr-24-23 03:07PM
Apr-21-23 12:19PM
Apr-20-23 11:45AM
Apr-19-23 12:05PM
Apr-18-23 10:01AM
Polaris Inc. engages in designing, engineering, and manufacturing power sports vehicles. It operates through the following segments: Off-Road, On-Road, and Marine. The Off-Road segment includes off-road vehicles (ORV) and snowmobiles. The On Road segment is involved in the design and manufacture of motorcycles, motorbikes, light duty hauling, and passenger vehicles. The Marine segment focuses on the design and manufacture of boats. The company was founded by Edgar E. Hetteen, Allan Hetten, and David Johnson in 1954 and is headquartered in Medina, MN.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Mack Robert Paul CFO, EVP - Finance + Corp Dev Aug 07 '23 Option Exercise 84.58 8,312 703,029 36,668 Aug 08 05:25 PM Mack Robert Paul CFO, EVP - Finance + Corp Dev Aug 07 '23 Sale 130.00 8,312 1,080,560 28,356 Aug 08 05:25 PM FARR KEVIN M Director Aug 03 '23 Sale 133.28 3,225 429,828 14,645 Aug 07 05:03 PM Eastman Stephen L. President - PG&A + Aftermarket Jul 28 '23 Option Exercise 125.67 10,000 1,256,700 27,800 Aug 01 06:20 PM Duke Benjamin D President-Marine Jul 28 '23 Option Exercise 105.63 1,454 153,583 5,969 Aug 01 06:19 PM Eastman Stephen L. President - PG&A + Aftermarket Jul 28 '23 Sale 135.82 10,000 1,358,200 17,800 Aug 01 06:20 PM Speetzen Michael T CEO Jul 28 '23 Sale 135.81 2,540 344,957 53,527 Jul 31 09:38 PM Clark Dougherty Lucy SVP-Gen Counsel & Secretary Jul 27 '23 Option Exercise 114.19 38,887 4,440,479 57,301 Jul 31 09:48 PM Speetzen Michael T CEO Jul 27 '23 Option Exercise 84.58 45,932 3,884,929 101,999 Jul 31 09:38 PM Dougherty Michael D. President - On Road and Int'l Jul 27 '23 Option Exercise 100.14 21,124 2,115,388 43,515 Jul 31 09:37 PM Speetzen Michael T CEO Jul 27 '23 Sale 136.14 58,301 7,937,131 56,067 Jul 31 09:38 PM Clark Dougherty Lucy SVP-Gen Counsel & Secretary Jul 27 '23 Sale 134.67 38,887 5,237,018 18,414 Jul 31 09:48 PM Dougherty Michael D. President - On Road and Int'l Jul 27 '23 Sale 135.99 21,124 2,872,694 22,391 Jul 31 09:37 PM FARR KEVIN M Director Jul 27 '23 Sale 134.33 1,615 216,943 17,870 Jul 31 09:33 PM Williams James P SVP-CHRO Jul 12 '23 Option Exercise 125.67 14,000 1,759,380 30,001 Jul 13 07:38 PM Williams James P SVP-CHRO Jul 12 '23 Sale 130.00 14,000 1,820,000 16,001 Jul 13 07:38 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite